Complement Therapeutics

Athanasios Didangelos is a seasoned biotech disease biologist with over 20 years of experience in translational research, focusing on target discovery and pharmacology in gene therapy. Currently serving as Vice President at Complement Therapeutics, Athanasios leads efforts in advancing gene therapy candidates for age-related macular degeneration and other neurodegenerative diseases. Previously, Athanasios has held significant roles, including Director of Translational Research at Droia Labs and Group Leader at Galapagos, where extensive work was done in proteomics and pathway discovery. Athanasios earned a PhD in Cell Biology from Imperial College London and a BSc in Anatomical Sciences from Cardiff University.

Complement Therapeutics' headquarters in London, United Kingdom

Org chart

Teams

Offices